Literature DB >> 19270462

Psychomotor changes in major depressive disorder during sertraline treatment.

D Schrijvers1, Y J Maas, M P B I Pier, Y Madani, W Hulstijn, B G C Sabbe.   

Abstract

BACKGROUND: There is a relative scarcity of studies on major depressive disorder that use objective assessment methods to explore the psychomotor effects of antidepressants. Striatal dopaminergic disturbances are known to be involved in the pathogenesis of major depressive disorder that is associated with psychomotor retardation. Because of its additional dopaminergic mechanism, the psychomotor effects of the selective serotonin reuptake inhibitor sertraline merit further exploration.
METHODS: In 19 patients diagnosed with a current major depressive episode, clinical variables and graphic motor activity were assessed applying digitized figure copying tasks during a 6-week regimen of sertraline. Patients' baseline and weekly psychomotor performance was compared with the outcomes of 22 healthy, unmedicated controls.
RESULTS: Patients' psychomotor slowing had improved after 6 weeks on sertraline as reflected by reductions in initiation and movement times on the simple line and figure copying tasks and decreased initiation times for the complex figure copying task relative to their baseline outcomes.
CONCLUSIONS: The current study found evidence pointing to potential beneficial effects of sertraline after a 6-week treatment period in the lower-order cognitive and motor components involved in the graphic motor performance of depressed patients. The present findings are discussed in terms of the mechanism of action of sertraline. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19270462     DOI: 10.1159/000205516

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  8 in total

1.  Internally vs. externally triggered movements in patients with major depression.

Authors:  Felix Hoffstaedter; Jan Sarlon; Christian Grefkes; Simon B Eickhoff
Journal:  Behav Brain Res       Date:  2011-11-28       Impact factor: 3.332

Review 2.  Psychomotor retardation in depression: biological underpinnings, measurement, and treatment.

Authors:  Jeylan S Buyukdura; Shawn M McClintock; Paul E Croarkin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-10-31       Impact factor: 5.067

3.  Effects of task-relevant incentives on the electrophysiological correlates of error processing in major depressive disorder.

Authors:  Avram J Holmes; Diego A Pizzagalli
Journal:  Cogn Affect Behav Neurosci       Date:  2010-03       Impact factor: 3.282

4.  Participation of brainstem monoaminergic nuclei in behavioral depression.

Authors:  Yan Lin; Yasmeen Sarfraz; Ashley Jensen; Adrian J Dunn; Eric A Stone
Journal:  Pharmacol Biochem Behav       Date:  2011-08-26       Impact factor: 3.533

Review 5.  Impact of pharmacological and psychological treatment methods of depressive and anxiety disorders on cognitive functioning.

Authors:  Krzysztof Krysta; Marek Krzystanek; Małgorzata Janas-Kozik; Adam Klasik; Irena Krupka-Matuszczyk
Journal:  J Neural Transm (Vienna)       Date:  2014-07-31       Impact factor: 3.575

6.  Increased Force Variability Is Associated with Altered Modulation of the Motorneuron Pool Activity in Autism Spectrum Disorder (ASD).

Authors:  Zheng Wang; Minhyuk Kwon; Suman Mohanty; Lauren M Schmitt; Stormi P White; Evangelos A Christou; Matthew W Mosconi
Journal:  Int J Mol Sci       Date:  2017-03-25       Impact factor: 5.923

Review 7.  Cognitive remission: a novel objective for the treatment of major depression?

Authors:  Beatrice Bortolato; Kamilla W Miskowiak; Cristiano A Köhler; Michael Maes; Brisa S Fernandes; Michael Berk; André F Carvalho
Journal:  BMC Med       Date:  2016-01-22       Impact factor: 8.775

Review 8.  Influence of Pharmacotherapy on Cognitive Functions in Depression: A Review of the Literature.

Authors:  Agata Orzechowska; Maria Filip; Piotr Gałecki
Journal:  Med Sci Monit       Date:  2015-11-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.